ClearPoint Neuro (CLPT) vs Standard BioTools (LAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Standard BioTools (LAB) has outperformed ClearPoint Neuro (CLPT) over the past year, losing 47.8% versus a loss of 59.6%. Over five years, CLPT leads with a -40.6% price change compared with -87.3% for LAB. ClearPoint Neuro is the larger company by market cap ($325.2 million vs $266.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLPT | LAB |
|---|---|---|
| Share price | $10.66 | $0.6787 |
| Market cap | $325.18M | $266.44M |
| 1-day change | -3.18% | -6.00% |
| YTD return | -22.08% | -46.98% |
| 1-year return | -59.61% | -47.79% |
| 5-year return | -40.65% | -87.29% |
| EPS (TTM) | $-1.14 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.10 | $1.72 |
| 52-week low | $8.27 | $0.63 |
| Distance from 52-week high | -64.58% | -60.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +120.45% | +98.91% |
| Average volume | 639.50K | 1.57M |
| Shares outstanding | 30.50M | 392.58M |
| Employees | 160 | 385 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LAB has outperformed CLPT by 11.8 percentage points over the past year.
About ClearPoint Neuro
CLPT stock →ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Healthcare · Medical Devices · 160 employees
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Healthcare · Medical Devices · 385 employees
CLPT vs LAB FAQ
Which is bigger, ClearPoint Neuro or Standard BioTools?
ClearPoint Neuro (CLPT) is larger, with a market capitalization of $325.18M compared with $266.44M for Standard BioTools (LAB).
Which stock has performed better over the past year, CLPT or LAB?
LAB returned -47.79% over the past 12 months, compared with -59.61% for CLPT (price return, excluding dividends). Past performance does not predict future results.
Are ClearPoint Neuro and Standard BioTools in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.